PA
AVIR icon

Parallel Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Parallel Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35
Closed – – 2962
2021
Q4 		$0 Sell
35
-55
-61% -$857 ﹤0.01% 3076
2021
Q3 		$3K Buy
90
+47
+109% +$1.3K ﹤0.01% 2539
2021
Q2 		$1K Buy
+43
New +$1.29K ﹤0.01% 2689

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors's AVIR Position: Q1 2022 in Review

Parallel Advisors sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 35 shares.

Parallel Advisors first reported a position in AVIR in Q2 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Parallel Advisors reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Parallel Advisors sold 35 Atea Pharmaceuticals shares in Q1 2022.
  • Parallel Advisors first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Parallel Advisors's Atea Pharmaceuticals position peaked at $3K in Q3 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Parallel Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.